{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Stable disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"groups":[{"description":"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\ntemsirolimus: Given IV","id":"OG000","title":"Treatment (Temsirolimus)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Tumor Response Rate, in Terms of the Proportion of Confirmed Tumor Responses (CR or PR) Assessed Using RECIST","type":"PRIMARY","unitOfMeasure":"participants"}